Literature DB >> 4720765

Clinical experience with the Dalkon Shield intrauterine device.

R W Jones, A Parker, M Elstein.   

Abstract

Preliminary acceptability and reliability tests of the Dalkon Shield were done in 377 women over 17 months, amounting to 3,028 months of use. There was a 98% follow-up. The pregnancy rate of 4.7 and expulsion rate of 6.3 do not meet the claims described in initial trials by the developers of the device. Nevertheless, the Dalkon Shield seems to be an advance in intrauterine contraception since it has the advantages of a lower expulsion rate than the "first generation" inert intrauterine devices.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4720765      PMCID: PMC1586323          DOI: 10.1136/bmj.3.5872.143

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  3 in total

1.  The shield intrauterine device. A superior modern contraceptive.

Authors:  H J Davis
Journal:  Am J Obstet Gynecol       Date:  1970-02-01       Impact factor: 8.661

2.  Biologic mode of action of the Lippes loop in intrauterine contraception.

Authors:  N Sağiroğlu; E Sağiroğlu
Journal:  Am J Obstet Gynecol       Date:  1970-02-15       Impact factor: 8.661

3.  Endometrial leukocytes in patients using intrauterine contraceptive devices.

Authors:  A Sedlis; J V Reyniak
Journal:  Am J Obstet Gynecol       Date:  1970-12-15       Impact factor: 8.661

  3 in total
  2 in total

1.  Comparison of use of the Dalkon Shield in Dublin and Southampton.

Authors:  J F Miller; R Snowden; J T Loughran; M Elstein
Journal:  Br Med J       Date:  1975-06-14

2.  Aminocaproic acid and menstrual loss in women using intrauterine devices.

Authors:  J M Kasonde; J Bonnar
Journal:  Br Med J       Date:  1975-10-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.